Elcys Injection, Solution
NDC Package 51754-1008-4
Package Information
Elcys (cysteine hydrochloride) injection is eLCYS® is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. This formulation utilizes a injection, solution delivery system. Marketed by Exela Pharma Sciences, Llc, this product is identified by NDC 51754-1008 and is authorized under FDA application NDA210660.
Identification & Billing
- RxCUI: 1486165 - cysteine HCl 50 MG/ML Injectable Solution
- RxCUI: 1486165 - cysteine hydrochloride 50 MG/ML Injectable Solution
- RxCUI: 2671585 - ELCYS 50 MG/ML Injectable Solution
- RxCUI: 2671585 - cysteine hydrochloride 50 MG/ML Injectable Solution [Elcys]
- RxCUI: 2671585 - Elcys 50 MG/ML Injectable Solution
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 51754 - Exela Pharma Sciences, Llc
- 51754-1008 - Elcys
- 51754-1008-4 - 25 VIAL in 1 CARTON / 50 mL in 1 VIAL
- 51754-1008 - Elcys
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51754-1008). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51754-1008-4 identifies a specific commercial package of 25 vial in 1 carton / 50 ml in 1 vial of Elcys, a human prescription drug labeled by Exela Pharma Sciences, Llc. This injection, solution is formulated for intravenous use and contains cysteine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Exela Pharma Sciences, Llc on December 12, 2023. The current certification is valid through December 31, 2027.
How is this Exela Pharma Sciences, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51754100804. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.